
China SXT Pharmaceuticals SXTC
$ 2.01
4.29%
Annual report 2025
added 04-11-2026
China SXT Pharmaceuticals Depreciation & Amortization 2011-2026 | SXTC
Annual Depreciation & Amortization China SXT Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.3 K | 203 K | 250 K | 320 K | 345 K | 332 K | 181 K | 129 K | 94.4 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 345 K | 82.3 K | 215 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Celldex Therapeutics
CLDX
|
3.38 M | $ 34.55 | 2.04 % | $ 2.29 B | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Akari Therapeutics, Plc
AKTX
|
14 K | $ 5.8 | 13.28 % | $ 391 B | ||
|
Aligos Therapeutics
ALGS
|
930 K | $ 6.68 | -12.79 % | $ 66 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
55.7 M | $ 309.66 | -3.27 % | $ 40.6 B | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
31.6 M | $ 22.88 | 4.91 % | $ 1.07 B | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 3.04 | -1.3 % | $ 5 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
BioXcel Therapeutics
BTAI
|
300 K | $ 1.15 | 7.48 % | $ 14 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
1.27 M | $ 1.41 | 4.07 % | $ 363 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
548 K | $ 4.32 | 1.41 % | $ 462 M | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 24.53 | 1.41 % | $ 3.12 B | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
199 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | ||
|
Cabaletta Bio
CABA
|
1.65 M | $ 3.44 | -2.27 % | $ 346 M | ||
|
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.6 | -0.62 % | $ 426 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
28 M | - | - | $ 546 M | ||
|
Citius Pharmaceuticals
CTXR
|
1.43 K | $ 0.86 | 0.39 % | $ 5.79 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Cidara Therapeutics
CDTX
|
154 K | - | - | $ 1.41 B | ||
|
CymaBay Therapeutics
CBAY
|
681 K | - | - | $ 3.45 B |